TrialBreast cancer research and treatment2019

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.

H S Rugo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.